Nikhil I Khushalani, MD
Amatore F et al. Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC). ASCO 2024;Abstract 9591.
Gross ND et al. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: Follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol 2023;24(11):1196-205. Abstract
Ladwa R et al. A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate. ASCO 2024;Abstract 9514.
Ladwa R et al. Using serial 18F-FDG PET/CT PERCIST response to predict responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma. ASCO 2024;Abstract 9548.
Lewis KD et al. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol 2024;35(2):221-8. Abstract
Muñoz-Couselo E et al. Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study. ASCO 2024;Abstract 9554.
Stratigos AJ et al. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. J Am Acad Dermatol 2024;90(2):414-8. Abstract
Jason J Luke, MD
Baramidze A et al. A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma. ASCO 2023;Abstract TPS9602.
Blank CU et al. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma,: The phase 3 NADINA trial. ASCO 2024;Abstract LBA2.
Hauschild A et al. Long-term follow-up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results from the COMBI-AD study. ASCO 2024;Abstract 9500.
Kirkwood JM et al. Adjuvant nivolumab in resected stage IIB/C melanoma: Primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med 2023;29(11):2835-43. Abstract
Larkin J et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res 2023;29(17):3352-61. Abstract
Luke JJ et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIb or IIc melanoma: Final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study. J Clin Oncol 2024;42(14):1619-24. Abstract
Sarnaik AA et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol 2021;39(24):2656-66. Abstract
Tawbi HA et al. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years. ASCO 2024;Abstract 9524.
Thomas S et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 Cohort 1A. ASCO 2024;Abstract 9505.
Weber JS et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update form the mRNA-4157-P201 (KEYNOTE-942) trial. ASCO 2024;Abstract LBA9512.